This preview has intentionally blurred sections. Sign up to view the full version.View Full Document
Unformatted text preview: Fax +41 61 306 12 34 E-Mail [email protected] www.karger.com Original Paper Digestion 2010;81:78–85 DOI: 10.1159/000253855 Clinical Experience with Adalimumab in a Multicenter Swiss Cohort of Patients with Crohn’s Disease Cristina Nichita a Marc Stelle a Stephan Vavricka b Abdou El-Wafa Ali c Pierluigi Ballabeni d Philippe de Saussure e Alex Straumann f Gerhard Rogler b Pierre Michetti a a Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne , b Department of Internal Medicine, Division of Gastroenterology, University Hospital, Zurich , c Pourtalès Hospital, Neuchâtel, d Institute of Social and Preventive Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, e Division of Hepatogastroenterology, Geneva University Hospital, Geneva, and f Department of Gastroenterology, Kantonsspital, Olten, Switzerland Results: The charts of 55 patients were reviewed; remission and response rates observed at weeks 4–6 were 52.7 and 83.6%, respectively. Remission was maintained at weeks 12, 24 and 52 in 89.6, 72.4 and 44.7% of patients, respectively. Remission and response rates were not influenced by smok- ing status, disease location or duration, the first month total dose, or previous infliximab therapy. The remission rate at weeks 4–6 was significantly higher in patients intolerant of infliximab as compared to those who lost response to this drug. Adalimumab was well tolerated overall. Conclusion: Adalimumab can be considered a suitable option in patients with moderate-to-severe CD, demonstrating sustained long- term effectiveness. Copyright © 2010 S. Karger AG, Basel Key Words Crohn’s disease ? Adalimumab ? Response, adalimumab ? Remission, Crohn’s disease Abstract Background: Controlled clinical trials have demonstrated the efficacy and safety of adalimumab in patients with mod- erate-to-severe Crohn’s disease (CD), but there is, however, only limited long-term experience with adalimumab in daily practice. Aim: To assess the long-term effectiveness and safety of adalimumab in a multicenter cohort of practice- based patients with moderate-to-severe CD. Methods: We retrospectively reviewed the charts of CD patients who re- ceived adalimumab over a 3-year period. Disease severity was scored using the Harvey-Bradshaw index (HBI). Remis- sion was defined as an HBI of ^ 4 and response as a reduc- tion in the HBI of 1 3 points at evaluation compared to the baseline. Univariate logistic regression analysis was used to identify the predictive variables associated with response. Received: April 30, 2009 Accepted: October 5, 2009 Published online: January 12, 2010 Cristina Nichita, MD Department of Gastroenterology and Hepatology Centre Hospitalier Universitaire Vaudois Rue du Bugnon, 46, CH–1011 Lausanne (Switzerland) Tel. +41 21 31 40 706, Fax +41 21 31 40 707, E-Mail cristina.nichita @ chuv.ch © 2010 S. Karger AG, Basel 0012–2823/10/0812–0078$26.00/0 0012–2823/10/0812–0078$26....
View Full Document
This note was uploaded on 10/20/2010 for the course LING 2654 taught by Professor Ambry during the Spring '10 term at San Diego.
- Spring '10